A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial).
<p>INTRODUCTION: Malaria due to Plasmodium knowlesi is reported throughout South-East Asia, and is the commonest cause of it in Malaysia. P. knowlesi replicates every 24 h and can cause severe disease and death. Current 2010 WHO Malaria Treatment Guidelines have no recommendations for the opti...
Egile Nagusiak: | Grigg, M, William, T, Dhanaraj, P, Menon, J, Barber, B, von Seidlein, L, Rajahram, G, Price, R, Anstey, N, Yeo, T |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
BMJ Group
2014
|
Antzeko izenburuak
-
Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): An open-label, randomised controlled trial
nork: Grigg, M, et al.
Argitaratua: (2015) -
Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: An open-label, randomized, controlled trial.
nork: Grigg, M, et al.
Argitaratua: (2016) -
Efficacy of Artesunate-mefloquine for Chloroquine-resistant
Plasmodium vivax
Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
nork: Grigg, Matthew J., et al.
Argitaratua: (2016) -
Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria (CAN KNOW): an open-label randomized controlled trial
nork: Grigg, M, et al.
Argitaratua: (2017) -
Deaths due to <it>Plasmodium knowlesi</it> malaria in Sabah, Malaysia: association with reporting as <it>Plasmodium malariae</it> and delayed parenteral artesunate
nork: Rajahram Giri S, et al.
Argitaratua: (2012-08-01)